… that rivaroxaban is not inferior to warfarin in terms of safety … and hospitals to evaluate
rivaroxaban effectiveness in real-life … knowledge, rivaroxaban effectiveness and safety have never …

… Using MarketScan data from January 2012 to December 2017, we identified oral anticoagulant
(OAC)-naïve NVAF patients receiving rivaroxaban (15–20 mg once daily) or warfarin, …

… In conclusion, results from our study of NVAF patients ≥80 years of age found consistent
effectiveness and safety results for rivaroxaban vs. warfarin as reported in ROCKET-AF. …

… (FDA) approved rivaroxaban. Since its introduction, rivaroxaban has served as an … to
evaluate the appropriateness of rivaroxaban dosing, indication and safety in a community …

… 150 mg twice daily and rivaroxaban 20 mg once daily) with NVAF in Denmark, July 2013 to
March 2016. Patients were matched on … dabigatran (for a total of 6470 patients), apixaban vs. …

… effectiveness and safety of rivaroxaban and warfarin in NVAF patients with co-morbid HF. …
and safety of rivaroxaban vs. warfarin in people with NVAF and HF treated in routine practice. …

… its effectiveness and safety at low doses remain unclear among Asians with NVAF. The objective
of the … and safety of low-dose rivaroxaban to those of warfarin among Asians with NVAF. …

… , rivaroxaban and SOC are often prescribed to patients with … proportion of patients receiving
rivaroxaban had previously … a ‘safer’ rivaroxaban population, it is notable that patients with a …

… warfarin in patients with NVAF. Therefore, we sought to assess the effectiveness and safety
of rivaroxaban vs. warfarin in NVAF patients with a non-sex-related CHA 2 DS 2 -VASc score …

… the efficacy and safety of rivaroxaban of Japanese specific dosages in NVAF patients. … This
study showed the outcomes following rivaroxaban treatment for Japanese NVAF patients in …